228 related articles for article (PubMed ID: 28646606)
1. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient.
Koelblinger P; Dummer R; Laimer M; Hecht S; Bauer JW; Gaggl A; Kugler A
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e7-e8. PubMed ID: 28646606
[No Abstract] [Full Text] [Related]
2. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
[No Abstract] [Full Text] [Related]
3. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
Zargari O; Azimi SZ; Geranmayeh S
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
Cusack CA; Nijhawan R; Miller B; Henien M; Malat G; Doyle A; Abdelmalek M
JAMA Dermatol; 2015 Jan; 151(1):70-2. PubMed ID: 25337679
[TBL] [Abstract][Full Text] [Related]
5. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
[No Abstract] [Full Text] [Related]
6. Reversible cutaneous side effects of vismodegib treatment.
Kwong B; Danial C; Liu A; Chun KA; Chang AL
Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
[No Abstract] [Full Text] [Related]
7. Four-year experience with vismodegib hedgehog inhibitor therapy.
Simone PD; Schwarz JM; Strasswimmer JM
J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
[No Abstract] [Full Text] [Related]
8. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
[TBL] [Abstract][Full Text] [Related]
9. Vismodegib (Erivedge) for basal cell carcinoma.
Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
[No Abstract] [Full Text] [Related]
10. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
11. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
[TBL] [Abstract][Full Text] [Related]
12. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
Kutiel TS; Vornicova O; Bar-Sela G
J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
[No Abstract] [Full Text] [Related]
13. Epidermal cyst formation and hyperkeratosis in a patient treated with vismodegib for locally advanced Basal cell carcinoma.
Reinders MG; Brinkhuizen T; Soetekouw PM; Kelleners-Smeets NW; Hamid MA; Mosterd K
Acta Derm Venereol; 2015 May; 95(5):618-9. PubMed ID: 25425396
[No Abstract] [Full Text] [Related]
14. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.
Aasi S; Silkiss R; Tang JY; Wysong A; Liu A; Epstein E; Oro AE; Chang AL
JAMA Dermatol; 2013 Feb; 149(2):242-3. PubMed ID: 23426496
[No Abstract] [Full Text] [Related]
15. Drug hypersensitivity syndrome in a patient receiving vismodegib.
Lam T; Wolverton SE; Davis CL
J Am Acad Dermatol; 2014 Mar; 70(3):e65-6. PubMed ID: 24528922
[No Abstract] [Full Text] [Related]
16. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
Orouji A; Goerdt S; Utikal J; Leverkus M
Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
[No Abstract] [Full Text] [Related]
17. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
Wolfe CM; Green WH; Cognetta AB; Hatfield HK
Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
[No Abstract] [Full Text] [Related]
18. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib in real-life clinical settings: A multicenter, longitudinal cohort providing long-term data on efficacy and safety.
Apalla Z; Spyridis I; Kyrgidis A; Lazaridou E; Kyriakou A; Fotiadou C; Pikou O; Sotiriou E; Vakirlis E; Papageorgiou C; Delli F; Moutsoudis A; Manoli SM; Ioannides D; Lallas A
J Am Acad Dermatol; 2021 Dec; 85(6):1589-1592. PubMed ID: 33253837
[No Abstract] [Full Text] [Related]
20. Follicular and cystic regression of locally advanced basal cell carcinoma following short-term neoadjuvant vismodegib therapy.
Mohr M; Schumacher N; Zillikens D; Terheyden P
J Dtsch Dermatol Ges; 2017 Oct; 15(10):1031-1033. PubMed ID: 28898543
[No Abstract] [Full Text] [Related]
[Next] [New Search]